Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone
复制标题
DOI：
10.4088/jcp.v62n0404
复制
发表时间：
2001-04-01
影响因子：
5.3
通讯作者：
Tollefson, GD
中科院分区：
文献类型：
--
作者：
Basson, BR;Kinon, BJ;Tollefson, GD
目的：预测体重变化的精神分裂症和相关疾病患者在急性治疗期间与抗精神病药物奥氮平，利培酮，氟哌啶醇的临床因素被要求通过回顾性analysis.Method：6周体重数据从2个试验，研究1比较奥氮平和氟哌啶醇（N = 1369）和研究2奥氮平和利培酮（N = 268），进行了分析。8个临床相关的协变量治疗，临床结果（简明精神病评定量表），基线体重指数（BBMI），食欲增加，年龄，性别，种族，和剂量对weight compared.Results的影响：在研究1中，奥氮平（与氟哌啶醇）治疗，更好的临床结果，较低的BBMI，和非白人种族显着影响体重增加。食欲增加和男性性别对体重增加的影响在奥氮平组中显著，但在氟哌啶醇组中不显著。在研究2中，更好的临床结果，更低的BBMI和更年轻的年龄显着影响体重增加。奥氮平治疗期间食欲增加的发生率高于氟哌啶醇治疗期间，但与利培酮治疗期间无显著差异。奥氮平与氟哌啶醇之间对体重变化的影响存在显着差异，但奥氮平与利培酮之间无显着差异。没有证据表明，较低的抗精神病药物剂量与较低的体重gain.Conclusion：本报告确定了精神分裂症患者急性体重变化的预测因素。抗精神病药物中预测体重增加更大的相似因素包括更好的临床结果，低BBMI和非白人种族。传统（氟哌啶醇）和非典型（奥氮平）药物之间的差异因素包括食欲增加和性别。选择非典型抗精神病药物（奥氮平vs利培酮）对急性体重增加的影响不太重要。
Objective: Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses.Method: Six-week body-weight data from 2 trials, study 1 comparing olanzapine and haloperidol (N = 1369) and study 2 olanzapine and risperidone (N = 268), were analyzed. Effects of 8 clinically relevant covariates-therapy, clinical outcome (Brief Psychiatric Rating Scale), baseline body mass index (BBMI), increased appetite, age, gender, race, and dose-on weight were compared.Results: In study 1, olanzapine (vs. haloperidol) therapy, better clinical outcome, lower BBMI, and nonwhite race significantly affected weight gain. Effects of increased appetite and male gender on weight gain were significant for olanzapine but not for haloperidol. In study 2, better clinical outcome, lower BBMI, and younger age significantly affected weight gain. Increased appetite was more frequent during olanzapine treatment than during haloperidol, but not significantly different from risperidone. Significant differences in effect on weight change were found between olanzapine and haloperidol but not between olanzapine and risperidone. No evidence was found that lower antipsychotic drug doses were associated with lower weight gain.Conclusion: This report identifies predictive factors of acute weight change in patients with schizophrenia. Similar factors across antipsychotic drugs in predicting greater weight gain included better clinical outcome, low BBMI, and nonwhite race. Factors differing between conventional (haloperidol) and atypical (olanzapine) agents included increased appetite and gender. Choice of atypical antipsychotic drug (olanzapine vs, risperidone) was of minor importance with regard to influence on acute weight gain.